Drug Trial Radar · NCT07272629
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Dec 4, 2025
Primary completion
May 28, 2026
Study completion Jun 8, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, multicenter, randomized, double-blind, double-dummy, single dose, placebo- and positive-controlled, 4-sequence, 4-treatment, 4-period crossover study.
Conditions
- Cardiac Repolarization
- Healthy Volunteers
Interventions
BalinatunfibDrug
Pharmaceutical form: Tablet Route of administration: Oral
MoxifloxacinDrug
Pharmaceutical form: Tablet Route of administration: Oral
PlaceboDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the QT interval corrected using the Fridericia formula (QTcF) centrally assessed using a semi-automatic readingTime frame: Baseline to day 2
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit- Site Number : 8400002
Dallas, Texas
Labcorp Clinical Research- Site Number : 8400001
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.